Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, 55905, USA.
Dig Dis Sci. 2021 Nov;66(11):3951-3959. doi: 10.1007/s10620-020-06718-0. Epub 2020 Nov 25.
Retained gastric food (RGF) identified during esophagogastroduodenoscopy (EGD) is often attributed to gastroparesis. This retrospective study evaluated the prevalence of RGF, risk factors for RGF, and the association between RGF and delayed gastric emptying (GE).
The prevalence and odds ratios for RGF in patients with structural foregut abnormalities or medical risk factors for delayed GE were determined from 85,116 EGDs performed between 2012 and 2018. The associations between RGF, delayed GE, and medical comorbidities were evaluated in 2991 patients without structural abnormalities who had undergone EGD and gastric emptying scintigraphy. The relationship between medication use and RGF was evaluated in 249 patients without structural or medical risk factors for RGF.
RGF was identified during 3% of EGDs. The odds of RGF were increased in patients with type 1 diabetes (12%, OR 1.7, P ≤ 0.001), type 2 diabetes (6%, OR 1.4, P ≤ 0.001), gastroparesis (14%, OR 4.8, P ≤ 0.001), amyloidosis (5%, OR 1.7, P ≤ 0.001), and structural foregut abnormalities (6%, OR 2.6, P ≤ 0.001). Overall, the PPV of RGF for delayed GE was 55%. However, the PPV varied from 32% in patients without risk factors to 79% in patients with type 1 diabetes. Opioids, cardiovascular medications, and acid suppressants were associated with RGF.
RGF is common during EGD. The PPV of RGF for delayed GE varies depending on underlying risk factors (type 1 diabetes, type 2 diabetes, gastroparesis, and amyloidosis). Acid suppressants or antacids, cardiovascular medications, and opioids are associated with RGF independent of delayed GE.
在食管胃十二指肠镜检查(EGD)中发现的胃潴留物(RGF)通常归因于胃轻瘫。本回顾性研究评估了 RGF 的患病率、RGF 的危险因素以及 RGF 与胃排空延迟(GE)之间的关联。
从 2012 年至 2018 年进行的 85116 次 EGD 中确定了结构性前肠异常或 GE 延迟的医学危险因素患者中 RGF 的患病率和比值比。在 2991 例无结构性异常且接受 EGD 和胃排空闪烁显像的患者中评估了 RGF、延迟 GE 和医学合并症之间的关联。在 249 例无 RGF 的结构性或医学危险因素的患者中评估了药物使用与 RGF 的关系。
在 3%的 EGD 中发现了 RGF。1 型糖尿病(12%,OR 1.7,P≤0.001)、2 型糖尿病(6%,OR 1.4,P≤0.001)、胃轻瘫(14%,OR 4.8,P≤0.001)、淀粉样变性(5%,OR 1.7,P≤0.001)和结构性前肠异常(6%,OR 2.6,P≤0.001)患者 RGF 的几率增加。总体而言,RGF 对延迟 GE 的阳性预测值为 55%。然而,从无危险因素的患者的 32%到 1 型糖尿病患者的 79%,PPV 各不相同。阿片类药物、心血管药物和酸抑制剂与 RGF 相关。
RGF 在 EGD 中很常见。RGF 对延迟 GE 的阳性预测值取决于潜在的危险因素(1 型糖尿病、2 型糖尿病、胃轻瘫和淀粉样变性)。酸抑制剂或抗酸剂、心血管药物和阿片类药物与 RGF 相关,与延迟 GE 无关。